For research use only. Not for therapeutic Use.
Bebtelovimab(CAT: I040857) is a potent neutralizing monoclonal antibody targeting the SARS-CoV-2 spike protein. Engineered for high affinity and broad activity against emerging variants, it is designed to inhibit viral entry into host cells, reducing the severity of COVID-19 infection. Bebtelovimab has demonstrated strong efficacy in neutralizing resistant strains, making it a valuable option for antiviral research and therapeutic development. With its rapid action and enhanced stability, it offers potential for both prophylactic and therapeutic applications. Explore Bebtelovimab for advancing infectious disease research and the development of next-generation monoclonal antibody treatments.
| CAS Number | 2578319-11-4 |
| Purity | ≥95% |
